Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term AFQ056 safety study in adolescents with Fragile X syndrome
NL-OMON38786Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Changes in vital signs, laboratory assessments, and ECGs and 1 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NL-OMON38786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38786.